Board of Directors approved the consolidated financial report for the second quarter of 2022
· Issued by Lumosa Therapeutics Co Ltd
Close
Today's Information
Provided by: LUMOSA THERAPEUTICS CO., LTD.
SEQ_NO
1
Date of announcement
2022/08/09
Time of announcement
15:20:47
Subject
LUMOSA Board of Directors approved the
consolidated financial report for the second quarter of
2022
Date of events
2022/08/09
To which item it meets
paragraph 31
Statement
1.Date of the board of directors submitted or approved:2022/08/09
2.Date of the audit committee approved:2022/08/09
3.Start and end dates of financial reports or unaudited financial
information of the reporting period(XXXX/XX/XX~XXXX/XX/XX):
2022/01/01~2022/06/30
4.Operating revenue accumulated from 1/1 to end of the period
(thousand NTD):7,705
5.Gross profit (loss) from operations accumulated from 1/1 to end of
the period (thousand NTD):2,486
6.Net operating income (loss) accumulated from 1/1 to end of the period
(thousand NTD):(160,369)
7.Profit (loss) before tax accumulated from 1/1 to end of the period
(thousand NTD):(379,645)
8.Profit (loss) accumulated from 1/1 to end of the period
(thousand NTD):(379,645)
9.Profit (loss) during the period attributable to owners of parent
accumulated from 1/1 to end of the period (thousand NTD):(379,645)
10.Basic earnings (loss) per share accumulated from 1/1 to end of
the period (NTD):(2.34)
11.Total assets end of the period (thousand NTD):1,952,547
12.Total liabilities end of the period
(thousand NTD):210,731
13.Equity attributable to owners of parent end of the
period (thousand NTD):1,741,816
14.Any other matters that need to be specified:NA
